Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: Are we changing life expectancy?

Laryngoscope

Volumn 122, Issue 7, 2012, Pages 1507-1511

  Spector, Matthew E ^a   Chinn, Steven B ^a   Rosko, Andrew J ^a   Worden, Francis P ^a   Ward, P Daniel ^a   Divi, Vasu ^a   McLean, Scott A ^a   Moyer, Jeffrey S ^a   Prince, Mark E P ^a   Wolf, Gregory T ^a   Chepeha, Douglas B ^a   Bradford, Carol R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Distant metastasis; head and neck cancer; positron emission tomography scan; survival

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SMOKING; TUMOR LOCALIZATION;

CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84862865387     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23264     Document Type: Article

References (17)

1. Alvi A., Johnson JT,. Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck 1997; 19: 500-505.
2. Calhoun KH, Fulmer P, Weiss R, Hokanson JA,. Distant metastases from head and neck squamous cell carcinomas. Laryngoscope 1994; 104: 1199-1205.
3. Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS,. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001; 23: 1056-1060.
4. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G,. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25: 1255-1260.
5. Stokkel MP, ten Broek FW, Hordijk GJ, Koole R, van Rijk PP,. Preoperative evaluation of patients with primary head and neck cancer using dualhead 18fluorodeoxyglucose positron emission tomography. Ann Surg 2000; 231: 229-234.
6. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20: 4199-4208.
7. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18: 651-658.
8. Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002; 236: 208-217.
9. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002; 24: 127-135.
10. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 1997; 19: 666-674.
11. Lapela M, Eigtved A, Jyrkkio S, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000; 36: 858-867.
12. Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ,. F-18-fluoro-deoxy- glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/ pharyngeal cancer. Head Neck 2001; 23: 933-941.
13. Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283-289.
14. Argiris A, Li Y, Forastiere A,. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101: 2222-2229.
15. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
16. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-263.
17. Recondo G, Armand JP, Tellez-Bernal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 1991; 101: 494-501.